Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Portfolio Pulse from
The E.mbrace phase 3 clinical study for an extraintestinal pathogenic E. coli vaccine did not show sufficient efficacy in preventing invasive E. coli infections, according to an independent interim analysis.
February 13, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sanofi's E.mbrace phase 3 study for an E. coli vaccine did not demonstrate sufficient efficacy, potentially affecting the company's stock performance.
The failure of the E.mbrace phase 3 study to demonstrate sufficient efficacy could negatively impact Sanofi's stock as it may affect investor confidence and future revenue expectations from this vaccine candidate.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80